Qiagen

Qiagen inks ninth master collaboration agreement for companion diagnostics

Wednesday, November 12, 2014 03:26 PM

Qiagen, a Netherlands-based holding company, has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.

More... »


Qiagen, Astellas Pharma ink agreement to develop companion diagnostics

Wednesday, October 29, 2014 01:27 PM

Qiagen, a Netherlands-based provider of sample and assay technologies, has announced a master collaboration agreement with Astellas Pharma, an R&D-driven global pharmaceutical company headquartered in Japan, to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.

More... »


Qiagen, AstraZeneca collaborate for lung cancer patients

Monday, July 28, 2014 02:53 PM

Qiagen, a Netherlands-based holding company, has announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AZ's targeted therapy for non-small cell lung cancer (NSCLC).

More... »

Qiagen, Eli Lilly collaborate to co-develop companion diagnostics

Tuesday, June 3, 2014 11:17 AM

Qiagen, a Netherlands-based holding company, is collaborating with Eli Lilly to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.   

More... »

Qiagen, Exosome Diagnostics to develop diagnostics for cancer

Monday, January 13, 2014 11:42 AM

Qiagen, a Netherlands-based holding company, has expanded its strategic partnership with Exosome Diagnostics to develop a first-in-class, non-invasive molecular in-vitro diagnostics for use in diagnosing and monitoring patients.

More... »

Qiagen acquires Ingenuity Systems

Wednesday, May 1, 2013 10:30 AM

Qiagen, a Netherlands-based global provider of sample and assay technologies, has acquired Ingenuity Systems, a Redwood City, Calif.-based provider of software solutions to efficiently and accurately analyze and interpret the biological meaning of genomic data.

More... »

Qiagen acquires AmniSure International

Friday, May 4, 2012 02:59 PM

Netherlands holding company Qiagen has acquired AmniSure International, a privately owned Boston company that markets the AmniSure assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM), a condition in which fluid leaks from the amniotic sac prematurely. Financial terms were not disclosed.

More... »

WuXi AppTec Partners with Qiagen to Develop Biomarkers

Tuesday, January 12, 2010 06:11 AM

Chinese contract research organization (CRO) WuXi AppTec has entered into a partnership with Netherlands holding company Qiagen to provide biomarker development, validation and personalized healthcare diagnostics. Neither company provided the financial details of the agreement.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs